|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Renovis: Premium Company Profile |
|
|
|
|
€ 396,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Décembre 2007 |
Taille du document : |
45 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 86 pages | Octobre 2006 | Anglais
|
|
|
| Main
focus: |
drug discovery,nanotechnology,biotechnology,...,...
|
| Research
focus: |
market size and estimates,market definition, |
| Geographic
focus: |
usa,india,austria,france |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The UK piling Market 40 pages | Mai 2002 |
This report will enable you to:Analyse the size of the UK market for piling between 1997 and 2006Quantify the size of the UK market for piling, 1997-2006, by technique: - bored - driven - embedded |
365,00 €
|
| |
| |
OTC Cough and Cold Remedies in Germany 15 pages | Juillet 2002 |
The German market for OTC cough and cold remedies reached a value of Euro 972 million (US$ 918 million) in 2001, up 0.4% on the previous year. During the review period, the market grew by 9.4%, an |
198,00 €
|
| |
| |
The Cardiovascular Outlook 1998-2010 186 pages | Août 1999 |
In 1998, the global cardiovascular market expanded by 7.2%, growing in value from $60bn in 1997 to almost $65bn in 1998. Market expansion is being driven by expanding prevalent populations in t |
795,00 €
|
| |
| |
The Japanese Pharmaceutical Market Outlook 2001 142 pages | Août 2001 |
Although Japan is the second largest pharmaceutical market in the world, it has traditionally been a relative 'no-go' area for pre-eminent Western drug companies. Now, however, extensive cultur |
1 200,00 €
|
| |
| |
Healthcare In Northern Ireland 52 pages | Mai 2000 |
The Northern Ireland Presentation Includes:- The Structure Of The Health Service In Northern Ireland- Total Expenditure On Health & Personal Social Services- Number Of Inpatient Beds, BY Area- Occ |
327,00 €
|
| |
| |
Patient Power Outlook 2001 152 pages | Juillet 2001 |
The increase in patient power witnessed over the last decade has been driven by developments in healthcare systems, patient advocacy activity, the increasing influence of the media in healthcare issue |
955,00 €
|
| |
| |
Healthcare In Scotland 52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
The Diagnostics Outlook to 2005 130 pages | Février 1999 |
Diagnostic market : The current in vitro diagnostic (IVD) market is discussed, identifying how the market can be segmented according to country, end user, clinical speciality and disease area.
|
795,00 €
|
| |
| |
European Pharmaceutical Industry 35 pages | Juillet 2002 |
The Pharmaceutical industry remains one of Europe’s best performing sectors (employment, R&D and trade surplus). The world pharmaceutical market was worth an estimated € 392,640 million (at ex-fact |
600,00 €
|
| |
| |
Patient Power in the Pharmaceutical Industry: The shift towards more informed, more powerful consumers of drugs 119 pages | Juin 1999 |
The dramatic rise in patient power in recent years presents a new and challenging opportunity to pharmaceutical companies, healthcare providers and governments alike. A great need exists for ph |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Renovis: Premium Company Profile |
|
|
Introduction
Renovis is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics in the areas of neurological and inflammatory diseases. Using its proprietary drug discovery capabilities in medicinal chemistry, cell biology and chemical screening libraries, the company is discovering and developing drug candidates internally as well as with strategic partners.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Renovis, a small molecule drug discovering and developing company, has proprietary pipeline products such as P2X7 and P2X3 antagonists for pain that are in preclinical development stage. The company has collaborated with Pfizer for developing VR1 antagonist for the treatment of pain.
During 2002-2006, the company recorded all of its revenues under collaborative agreements with. Pfizer for VR1 program and AstraZeneca for NXY-059, which was suspended in 2006 on failing to meet the primary end points.
The total revenues increased from $5 million in 2003 to $10 million in 2006, primarily due to the increased upfront fees and milestone payments received from collaborative partners.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization
|
|
TABLE OF CONTENTS Overview 1 Catalyst 1 Summary 1 Company Structure 6 Company Overview and Key Facts 6 Business Description 7 History 8 Company Financials 10 Stock Market Performance 10 P&L 11 Balance Sheet 14 Cash Flow 14 Business Segment Performance 15 Products & Services 16 Pipeline Products 16 AC Forecast Product Sales 18 Competitors and Strategic Business Relationships 19 Key Competitors 19 Key Suppliers 19 Key Clients 20 Shareholding Structure 21 Strategy 22 Company View 22 Corporate Strategy 24 SWOT Analysis 26 Overview 26 Strengths 27 Weaknesses 28 Opportunities 29 Threats 31 Value Chain Analysis 32 Discovery and Product Development 33 Scorecard 34 Overview 34 Scorecard Analysis 35 Key Employees 36 List of Key Employees 36 Key Employee Biographies 37 Financial and Operational Overview 43 Financial and Operational Overview 43 APPENDIX 45 Ask the analyst 45 Datamonitor consulting 45 Disclaimer 45
TABLE OF FIGURES Figure 1: Renovis - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
TABLE OF TABLES Table 1: Renovis - Key Facts 6 Table 2: Renovis - Year-End Share Price and Market Capitalization, 2002-2006 ($) 10 Table 3: Renovis - Key Events Impacting Share Price Performance 10 Table 4: Renovis - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 11 Table 5: Renovis - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 13 Table 6: Renovis – Balance Sheet, 2002-2006 ($ Mn) 14 Table 7: Renovis – Cash Flow, 2002-2006 ($ Mn) 14 Table 8: Renovis - Revenue Breakdown by Division, 2002-2006 ($ Mn) 15 Table 9: Renovis - In-house Pipeline Products 16 Table 10: Renovis - Collaboration Products 17 Table 11: Renovis - Forecast Sales, 2006-2010 ($ Mn) 18 Table 12: Renovis - Key Competitors 19 Table 13: Renovis - Key Suppliers 19 Table 14: Renovis – Key Clients 20 Table 15: Renovis - Key Shareholders 21 Table 16: Renovis - SWOT Analysis Summary 26 Table 17: Renovis - Value Chain Analysis 32 Table 18: Renovis - Scorecard 34 Table 19: Renovis - Key Employees 36 Table 20: Renovis - Financial and Operational Overview 43
|
|
|
PPLSEN
|
|
|
|
|